CORD-19:4ca5d854d3f99440b507fd7dfae73c8ad6fc45d5 / 97472-97797 JSONTXT

{"project":"CORD-19-Sentences","denotations":[{"id":"T24783","span":{"begin":0,"end":325},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"The objective of this study was to predict the probabilities of attaining targeted pharmacodynamic exposure for clinically used dosing regimens of doripenem (DOR), imipenem/cilastatin (IPM), and meropenem (MEM) against a German collection of contemporary drug-resistant Gram-neg. pathogens using Monte Carlo simulation (MCS)."}

{"project":"CORD-19_Custom_license_subset","denotations":[{"id":"T7","span":{"begin":0,"end":325},"obj":"Sentence"}],"text":"The objective of this study was to predict the probabilities of attaining targeted pharmacodynamic exposure for clinically used dosing regimens of doripenem (DOR), imipenem/cilastatin (IPM), and meropenem (MEM) against a German collection of contemporary drug-resistant Gram-neg. pathogens using Monte Carlo simulation (MCS)."}

{"project":"CORD-19-PD-MONDO","denotations":[{"id":"T243","span":{"begin":206,"end":209},"obj":"Disease"},{"id":"T244","span":{"begin":320,"end":323},"obj":"Disease"},{"id":"T38658","span":{"begin":320,"end":323},"obj":"Disease"}],"attributes":[{"id":"A243","pred":"mondo_id","subj":"T243","obj":"http://purl.obolibrary.org/obo/MONDO_0008001"},{"id":"A244","pred":"mondo_id","subj":"T244","obj":"http://purl.obolibrary.org/obo/MONDO_0010666"},{"id":"A245","pred":"mondo_id","subj":"T244","obj":"http://purl.obolibrary.org/obo/MONDO_0019024"},{"id":"A43638","pred":"mondo_id","subj":"T38658","obj":"http://purl.obolibrary.org/obo/MONDO_0010666"},{"id":"A80992","pred":"mondo_id","subj":"T38658","obj":"http://purl.obolibrary.org/obo/MONDO_0019024"}],"text":"The objective of this study was to predict the probabilities of attaining targeted pharmacodynamic exposure for clinically used dosing regimens of doripenem (DOR), imipenem/cilastatin (IPM), and meropenem (MEM) against a German collection of contemporary drug-resistant Gram-neg. pathogens using Monte Carlo simulation (MCS)."}